

Weight Loss and Quality of Life in Patients Surviving 2 Years after Gastric Cancer Resection

Marta Climent¹ · Marina Munarriz¹ · Jane M. Blazeby² · Dimitri Dorcaratto¹ · José M. Ramón¹ · María J. Carrera³ · Laia Fontane³ · Luis Grande¹ · Manuel Pera¹

¹Section of Gastrointestinal Surgery, Hospital Universitari del Mar, IMIM (Hospital del Mar Medical Research Institute), Universitat Autònoma de Barcelona, Barcelona, Spain; ²School of Social and Community Medicine, University of Bristol, and University Hospital Bristol National Health Services Foundation Trust, Bristol, UK; ³Nutrition Unit, Service of Endocrinology, Hospital Universitari del Mar, Barcelona, Spain.

Running head: Quality of life after gastric cancer resection

Conflicts of interest: None to be disclosed by any of the authors

Corresponding author: Manuel Pera, MD, PhD, Section of Gastrointestinal Surgery, Hospital Universitari del Mar, Passeig Marítim 25-29, E-08003 Barcelona, Spain.

Phone: +34 93 2483207, fax: +34 932483433

e-mail: pera@parcdesalutmar.cat

ABSTRACT

Background: Malnutrition is common in patients undergoing gastric cancer resection, leading to weight loss, although little is known about how this impacts on health related quality of life (HRQL) This study aimed to explore the association between HRQL and weight loss in patients 2 years after curative gastric cancer resection.

Methods: Consecutive patients undergoing curative gastric cancer resection and surviving at least 2 years without disease recurrence were recruited. Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the specific module for gastric cancer (STO22) before and 2 years postoperatively and associations between HRQL scores and patients with and without $\geq 10\%$ body weight loss (BWL) were examined.

Results: A total of 76 patients were included, of whom 51 (67%) had $BWL \geq 10\%$. At 2 years postoperatively, $BWL \geq 10\%$ was associated with deterioration of all functional aspects of quality of life, with persistent pain (21.6%), diarrhoea (13.7%) and nausea/vomiting (13.7%). By contrast, none of the patients with $BWL < 10\%$ experienced severe nausea/vomiting, pain or diarrhoea.

Conclusions: Disabling symptoms occurred more frequently in patients with $\geq 10\%$ BWL than in those with $< 10\%$ BWL, with a relevant negative impact on HRQL. A cause-effect relationship between weight loss and postoperative outcome remains unsolved.

Key words: Gastric cancer; surgery; quality of life; weight loss

INTRODUCTION

Surgical resection, either alone or in combination with perioperative chemotherapy or adjuvant chemotherapy, or chemoradiation is the main curative treatment for locally advanced gastric cancer (1–3). Malnutrition has been widely recognized in gastric cancer patients because of the disease itself or because of the surgical and oncological treatments (4,5). Gavazzi et al.(5) analysed the nutritional status at the beginning of gastric cancer treatment and reported a body weight loss (BWL) $\geq 10\%$ of usual weight in 17% of patients, having a negative influence on health-related quality of life (HRQL). Several studies have defined HRQL as an important additional outcome measure in gastric cancer patients undergoing resection, showing differences between surgical techniques (6–8) as well as providing prognostic information (9–11).

A greater than 10% baseline BWL has been considered as a severe nutritional risk indicator in patients with gastrointestinal cancer (12,13). Previous studies have found that patients undergoing total gastrectomy will lose 7%-15% of their body weight, usually within the first year of surgery, and will not return to a pre-operative weight (14–16). The reduction in calorie intake as well as malabsorption are considered the main factors responsible for BWL(14). The extent of postoperative BWL seen postoperatively has been related to a deterioration of HRQL after oesophageal cancer resection (17).

Little is known, however, about long-term HRQL after gastrectomy and especially, how postoperative BWL may affect HRQL. In this study we assessed HRQL in patients surviving at least 2 years after curative gastric cancer resection. It was hypothesised that the magnitude of BWL may be related to HRQL impairment.

METHODS

Study population

Consecutive patients undergoing curative gastric cancer resection were recruited between October 2004 and May 2014 at Hospital Universitari del Mar (Barcelona, Spain). Total or subtotal gastric resection, depending upon the location and the extent of the tumour, with modified D2 lymphadenectomy was undertaken. A 70 cm Roux-en-Y loop reconstruction was performed in all cases. In the context of clinical trials carried out during the study period, perioperative chemotherapy or adjuvant chemoradiation was offered to a subgroup of patients with clinical stage II/III disease. Tumour stage was defined according to the system of the International Union Against Cancer(18). Postoperative complications were categorised according to a modified Clavien-Dindo classification(19). Sepsis was defined as an infection that had evoked a systemic inflammatory response syndrome (SIRS)(20).

Patients who had survived for at least 2 years without recurrence, and had completed the HRQL questionnaires were eligible for the study. Excluded were those who do not survive for 2 years after surgery with or without recurrence. Other exclusion criteria were concurrent malignancy, multivisceral resections, cognitive deterioration, and those who declined to complete the study questionnaires. **The Ethics Committee of Hospital Universitari del Mar approved the study and written informed consent was obtained from all participants.**

All patients were seen at the outpatient clinic by a medical oncologist and a surgeon at 3 months intervals during the first 2 years after surgery; and every 6 months until they completed 5 years postoperatively. After surgery, patients were referred to the Nutrition and Dietetic Outpatient Clinic for nutritional guidance,

although no specific strategy for the provision of oral nutritional supplements was instituted.

Assessment of preoperative and postoperative weight

Height and weight were measured at the first visit (less than 2 weeks) before the operation. Preoperative BWL was calculated using the formula average weight (kg) minus weight at time of surgery (kg) / average weight (kg) (14). Body mass index (BMI), using the standard formula weight (kg)/height (m²), was calculated at baseline and at 6, 12 and 24 months after surgery. The percentage of postoperative weight change was calculated using the formula weight at time of surgery (kg) minus current weight (kg) / weight at time of surgery (kg) at 6 months, 12 months and 2 years postoperatively.

Health-related quality of life

HRQL was assessed with the validated European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire, EORTC Quality of Life Questionnaire (QLQ-C30) (version 3.0) and the specific module for gastric cancer EORTC QLQ-STO22. Permission from EORTC was obtained in order to use them. EORTC QLQ-C30 is a 30-item questionnaire composed of multi-item scale and single items that reflects the multidimensionality of the quality of life in patients with cancer. It incorporates five functional scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea and vomiting) and a global health scale. It also includes single items commonly reported by cancer patients (10,21). The validated EORTC QLQ-STO22 contains 22 items structured in five scales (dysphagia, eating restrictions, pain, reflux and anxiety) and three single items (22). Patients were asked to complete the questionnaires by themselves at

home. If patients showed difficulties to understand questionnaires, additional help was provided. Baseline HRQL assessment was performed less than 2 weeks before surgery. Subsequent assessments during the follow-up period were carried out at 6, 12, and 24 months after surgery. When questionnaires were completed or returned, they were checked for missing response. If answers were absent, patients were asked to respond(9,11). If responses were still missing from more than half of the questions within a scale, these questionnaires were excluded from the analyses, according to EORTC recommendations(21,23).

All responses to the EORTC QLQ-C30 and STO-22 questionnaires were linearly transformed into scores from 0 to 100 to standardise the raw score. In the functional scales, high scores represent better quality of life (better function), whereas high scores in symptom scales and items represent worse problems with symptoms(9).

Data Analyses

Baseline characteristics and HRQL scores were analysed in relation to BWL < 10% or \geq 10% at 2 years. Based on previous studies, a cut-off of 10% was chosen because this percentage of BWL is considered as a severe nutritional risk marker (12–14,16). Mean scores and 95% confidence intervals (CIs) for HRQL were calculated preoperatively and at 2 years after surgery. Changes of 10 or more points on a 0 to 100 scale were considered clinically relevant(9,24). Statistical analyses were performed using *t* test and X^2 test. $P < 0.05$ was considered statistically significant (two-sided). Responses to symptom scales were dichotomised based on whether the patients reported minimal or severe symptoms, with “not at all” and “a little” categorised as minimal and “quite a bit” or “very much”

categorised as severe (25,26). The SPSS software package (SPSS Inc, Chicago, IL, USA), version 20.0, was used.

RESULTS

Demographics and Cohort Features

During the study period, 119 patients undergoing curative gastric cancer resection were recruited. Forty-three patients were excluded from the analysis due to reasons depicted in Figure 1. Thus, 76 patients remained for the final analysis. Of these patients, baseline measurement of HRQL was missing in four patients: one underwent emergency gastric resection and the other three patients did not complete them. Preoperative clinical and demographic characteristics in both groups are shown in Table 1. BWL \geq 10% at 2 years was detected in 51 patients (67%) whereas the rest of patients (25 patients) experienced BWL $<$ 10%. No differences were observed between both groups in any variable except for the type of gastrectomy and grade ASA.

HRQL 2 Years after Surgery in relation to weight loss

Patients with \geq 10% BWL at 2 years after surgery had lower scores in all items of the functional scales of EORTC QLQ-C30 but in none of them there were clinically relevant differences (mean reduction of $>$ 10 points) (Table 2). Of the symptoms reported, patients with \geq 10% BWL at 2 years postoperatively were generally more symptomatic than patients without such percentage of BWL. Clinically relevant differences were identified with pain, diarrhoea, eating restrictions and financial difficulties (Table 2). Results at 2 years after surgery showed that up to one third of patients reported symptoms categorised as severe (“quite a bit” or “very much”) with anxiety (Table 3). Moreover, more than one fifth of these patients

also reported severe problems with fatigue (20.4%), pain (21.6%), eating restrictions (29.4%), having dry mouth (25.5%) and body image (23.6%). In addition, 13.7% of patients with $BWL \geq 10\%$ experienced severe diarrhoea and severe nausea and vomiting (Table 3). By contrast, none of the patients with $BWL < 10\%$ experienced severe nausea/vomiting, pain or diarrhoea.

HRQL before Surgery in relation to weight loss

Most of the baseline functional scores were poorer in patients who subsequently experienced more than 10% of BWL compared to those without this extent of BWL (Table 2). However, only differences in role and physical function were clinically relevant (i.e. > 10 points different). Baseline symptoms scores were higher among patients with $BWL \geq 10\%$. Clinically relevant differences were only observed in relation to fatigue, pain and constipation. Results at baseline showed that one third of patients with $\geq 10\%$ BWL reported severe symptoms with anxiety (54.2%), fatigue (36.9%) and constipation (31.2%). Moreover, more than one fifth of these patients also reported severe symptoms with insomnia (25%), dry mouth (25%), appetite loss (22.9%) and pain (20.8%). Severe nausea and vomiting, dyspnoea and financial difficulties were only reported by patients that experienced $\geq 10\%$ BWL.

DISCUSSION

This prospective study examined the relation between HRQL and BWL in patients surviving 2 years after curative gastric cancer resection. In our study, 67% of patients experienced $\geq 10\%$ of BWL at 2 years of surgery. The patients with $\geq 10\%$ BWL after 2 years usually reported more symptoms compared with those patients with less BWL. It is of note that severe symptoms with nausea and

vomiting, pain and diarrhoea were only reported in patients with BWL over 10%. Preoperative measurement of HRQL allowed us to explore HRQL differences between patient groups before surgery. This showed that patients losing at least 10% of weight at 2 years experienced preoperatively more fatigue, pain, and constipation with a significant reduction in role and physical function as compared to patients with a lower percentage of BWL. Moreover, severe symptoms were more frequently reported in patients who experience more BWL at 2 years after surgery. These findings suggest some relation between weight loss and quality of life in long-term survivors after gastric cancer resection and it make us aware of the need for potential early interventions that could minimise this significant problem. The findings also provide us with information to inform future patients undergoing surgery for gastric cancer of postoperative symptoms that may occur and occasionally be severe.

A number of studies have described the great impact of gastric resection on HRQL in patients with curable gastric cancer (6,10). It has been shown that HRQL is influenced by the extent of resection (total vs. subtotal or proximal gastrectomy) (4,6) and there is a significant impairment of several aspects of HRQL reported by patients in the immediate postoperative period(6). Whilst studies show that symptoms improve after 6 or 12 months postoperatively, there is also evidence that some symptoms such as fatigue, nausea, pain or diarrhoea remain at 2 years after surgery as we observed in the present study (6,7). Other authors have investigated how baseline HRQL assessment may predict clinical outcomes (9,10). Avery et al. (10) reported worse global health, more nausea and vomiting, pain and fatigue at baseline assessment among those patients dying within 2 years after gastric cancer resection. A difference in the baseline dyspnoea score, measured by HRQL

questionnaires, was suggested by Djärv et al. (9) as an independent predictive factor of death, but in this study gastric and oesophageal resection cases were analysed together. These studies have used a variety of measures to assess HRQL including the Gastro intestinal Quality of Life Index, the FACT-G and the EORTC QLQ-C30 and QLQ-STO22 (as used in this study). Whilst these tools differ in their scoring systems and presentation they also cover very similar Quality of Life domains (e.g. nausea and vomiting, diarrhoea, etc). Improved consistency in what is measured in studies following surgery could be achieved by the use of Core Outcome Sets, which are an agreed minimum set of outcomes scientifically identified and reported in all studies of a particular condition (27). A Core Outcome Set for gastric cancer surgery is currently under development.

There are a few studies reporting the relation between postoperative malnutrition and HRQL (14,17,28). Although some of them have HRQL baseline assessment, none related HRQL to postoperative BWL. Our study identifies some baseline HRQL items related to long-term greater BWL. Two studies have previously described 7-15% of BWL after gastric cancer resection (14,15). Another study has even identified cachexia in half of the patients (9). In agreement with these previous studies, our results show that more than half of the patients experienced at least 10% of BWL after gastric cancer resection. These results highlight the need for more active clinical interventions to counteract malnutrition particularly in patients with ASA III-IV grade undergoing total gastrectomy. Starting nutritional counselling and oral nutritional supplementation before surgery should be considered, and especially increasing nutritional support within 6 months after surgery, when it seems represent the period of greatest weight loss according to our data (data not shown). Although nutritional intervention is recommended in the

management of BWL, there is still lack of evidence to support oral nutritional interventions as an individual strategy (29). Furthermore, physiotherapy, psychological assessment and other healthcare support might facilitate improvement in common symptoms reported by patients after gastric cancer resection, such as fatigue, deterioration in emotional function or pain control (30).

In line with our results, previous studies have found a high prevalence of diarrhoea after gastric cancer resection ranging from 20% to 30% (6,7,10,11). In the present study, severe diarrhoea was more common in the group of patients with $\geq 10\%$ BWL (13% versus 0%). In a recent systematic study of a prospective consecutive series of 45 disease-free patients after esophagectomy or gastrectomy, Henegham et al. (16) found that the incidence of malabsorption at 18 to 24 months postoperatively was 71% in the gastrectomy group. The proportion of patients with more than 15% weight loss had significantly lower nutritional risk index scores, and a higher incidence of malabsorption compared with those who had less than 15% weight loss at 24 months. Additionally, of those patients with malabsorption, 44% had exocrine pancreatic insufficiency and 38% had evidence of small intestinal bacterial overgrowth. Further studies are required to define a well-established diagnostic and therapeutic strategy for amelioration of malabsorption, including the substitution with pancreatic enzymes and the treatment of bacterial overgrowth, to reduce its incidence and potentially minimise BWL and improve HRQL after gastric resection.

A high incidence of nausea and vomiting has also been reported in patients undergoing gastrectomy, reaching 19% and 35% at 6 and 18 months respectively after surgery (6,11). It has been proposed that total gastrectomy may induce more nausea and vomiting than subtotal gastrectomy (31) due to early satiety,

oesophageal reflux, and dumping symptoms (32). In this sense, our prevalence of total gastrectomy is high, reaching 66%.

Although our data has been collected accurately, with high compliance even in the baseline assessment, the current study was not powered to perform a multivariate analysis introducing confounders to identify predictive factors for long-term BWL after curative gastric cancer resection. Moreover, It is a single centre study and a multicentre study would provide data that is more generalizable.

In summary, more than 50% of patients surviving 2 years after curative gastric cancer resection experienced $\geq 10\%$ BWL. Disabling symptoms such as persistent pain, nausea/vomiting and diarrhoea occurred more frequently in patients with $\geq 10\%$ BWL than in those with $< 10\%$ BWL. Disabling symptoms had a negative impact on HRQL. However, a cause-effect relationship between weight loss and postoperative outcome remains unsolved, and the present study was not intended to establish a cause and effect relationship. From a clinical point of view, early nutritional support and counselling in gastric cancer patients undergoing curative surgical treatment seems advisable, but whether extensive feeding recommendations lead to a reduction of disabling symptoms in these patients or do they have functional problems leading to disabling symptoms with BWL $\geq 10\%$ is a matter under discussion that could be clarified in future studies.

Acknowledgments

The authors wish to acknowledge Sergi Mojal, from the Statistics Unit, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques) for expert help in the statistical analysis, and Marta Pulido, MD, for editing the manuscript and editorial assistance. Blazeby was supported by the MRC ConDuCT-II Hub (**C**ollaboration and **i**nnovation for **D**ifficult and **C**omplex randomised controlled **T**rials In **I**nvasive procedures - MR/K025643/1).

Authors' contribution

M. Climent: Conception and design, collection of data, assessment of the HRQL, critical review of results and writing of the first draft, and approval of the final draft.

M. Munarriz: Conception and design, collection of data, critical review of results and approval of the final draft.

J. Blazeby: Conception and design, critical review of results and approval of the final draft.

D. Dorcaratto: Conception and design, critical review of results and approval of the final draft.

M.J Carrera: Nutritional follow-up of patients, critical review of results and approval of the final draft.

L. Fontane: Nutritional follow-up of patients, critical review of results and approval of the final draft.

L. Grande: Conception and design, critical review of results and writing of the first draft, and approval of the final draft.

M. Pera: Contribution of design and interpretation of results, critical review of results and writing of the first draft, and approval of the final draft.

LEGENDS:

Figure 1. Flow chart of patients included in the study with number of patients who completed the health-related quality of life (HRQL) questionnaires.

REFERENCES

1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van De Velde CJH, Nicolson M, et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. *New Engl J Med.* 2006;355:11–20.
2. Noh S, Park S, Yang H, Chung H, Chung I, Kim S, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol.* 2014;12:1389–96.
3. Macdonald J, Smalley SR, Benedetti J, Scott AH, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med.* 2001;345:725–30.
4. Luu C, Arrington AK, Falor A, Kim JAE, Lee B. Impact of Gastric Cancer Resection on Body Mass Index. *Am Surg.* 2014;80:1022–6.
5. Gavazzi C, Colatruglio S, Sironi A, Mazzaferro V, Miceli R. Importance of early nutritional screening in patients with gastric cancer. *Br J Nutr.* 2011;106:1773–8.
6. Karanicolas PJ. Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study. *Ann Surg.* 2013;257:1039–46.
7. Kim AR, Cho J, Hsu Y-J, Choi MG, Noh JH, Sohn TS, et al. Changes of Quality of Life in Gastric Cancer Patients After Curative Resection A Longitudinal Cohort Study in Korea. *Ann Surg.* 2012;256:1008–13.
8. Kobayashi D, Kodera Y, Fujiwara M, Koike M, Nakayama G, Nakao A. Assessment of quality of life after gastrectomy using EORTC QLQ-C30 and STO22. *World J Surg.* 2011;35:357–64.
9. Djärv T, Metcalfe C, Avery KNL, Lagergren P, Blazeby JM. Prognostic value of changes in health-related quality of life scores during curative treatment for esophagogastric cancer. *J Clin Oncol.* 2010;28:1666–70.
10. Avery K, Hughes R, McNair A, Alderson D, Barham P, Blazeby J. Health-related quality of life and survival in the 2 years after surgery for gastric

- cancer. *Eur J Surg Oncol*. 2010;36:148–54.
11. Barbour AP, Lagergren P, Hughes R, Alderson D, Barham CP, Blazeby JM. Health-related quality of life among patients with adenocarcinoma of the gastro-oesophageal junction treated by gastrectomy or oesophagectomy. *Br J Surg*. 2008;95:353–61.
 12. Martin L, Lagergren P. Long-term weight change after oesophageal cancer surgery. *Br J Surg*. 2009;96:1308–14.
 13. Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schütz T, et al. ESPEN Guidelines on Enteral Nutrition: Gastroenterology. *Clin Nutr*. 2006;25:260–74.
 14. Carey S, Storey D, Biankin A V., Martin D, Young J, Allman-Farinelli M. Long term nutritional status and quality of life following major upper gastrointestinal surgery - A cross-sectional study. *Clin Nutr*. 2011;30:774–9.
 15. Bae JM, Park JW, Yang HK, Kim JP. Nutritional status of gastric cancer patients after total gastrectomy. *World J Surg*. 1998;22:254–61.
 16. Heneghan H., Zaborowski A, Fanning M, McHugh A, Doyle S, Moore J, et al. Prospective study of malabsorption and malnutrition after esophageal and gastric cancer surgery. *Ann Surg*. 2015;262:803–8.
 17. Martin L, Lagergren P. Risk Factors for Weight Loss Among Patients Surviving 5 Years After Esophageal Cancer Surgery. *Ann Surg Oncol*. 2014;22:610–6.
 18. Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th Ed. Wiley-Blackwell. 2009;20–4.
 19. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg*. 2009;250:187–96.
 20. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. *Chest*. 1992;101:1481–3.
 21. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D BA. The EORTC QLQ-C30 Scoring Manual (3rd Edition). *Eur Organ Res Treat Cancer*.

- 2001;1–78.
22. Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. *Eur J Cancer*. 2004;40:2260–8.
 23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst*. 1993;85:365–76.
 24. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in Health-Related Quality-of-Life scores. *J Clin Oncol*. 1998;16:139–44.
 25. Derogar M, van der Schaaf M, Lagergren P. Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population. *Acta Oncol*. 2012;51:10–6.
 26. Djärv T, Blazeby JM, Lagergren P. Predictors of postoperative quality of life after esophagectomy for cancer. *J Clin Oncol*. 2009;27:1963–8.
 27. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Garzon E, et al. *Trials*. 2012; 13:132.
 28. Marín Caro MM, Laviano A, Pichard C. Impact of nutrition on quality of life during cancer. *Curr Opin Clin Nutr Metab Care*. 2007;10:480–7.
 29. Baldwin C. The effectiveness of nutritional interventions in malnutrition and cachexia. *Proc Nutr Soc*. 2015;74:397–404.
 30. Martin L, Lagergren J, Lindblad M, Rouvelas I, Lagergren P. Malnutrition after oesophageal cancer surgery in Sweden. *Br J Surg*. 2007;94:1496–500.
 31. Davies J, Johnston D, Sue-Ling H, Young S, May J, Griffith J, et al. Total or subtotal gastrectomy for gastric carcinoma? A study of quality of life. *World J Surg*. 1998;22:1048-55.
 32. Bradley EL, Isaachs J, Hersh T, Davidson ED, Millikan W. Nutritional consequences of total gastrectomy. *Ann Surg*. 1975;4:415-29.

Table 1. Baseline and clinical characteristics of 76 patients who survived at least 2 years after curative gastric cancer resection in relation to weight loss \geq or $<$ 10% at 2 years

Characteristics	Entire group N = 76	Weight Loss < 10% N = 25	Weight Loss \geq 10% N = 51	P value
Sex				
Female	31	11	20	0.69
Male	45	14	31	
Age, years				
< 75	39	14	25	0.56
\geq 75	37	11	26	
ASA, grade				
I - II	43	19	24	0.017
III - IV	33	6	27	
Preoperative weight loss				
< 10 %	62	20	42	0.80
\geq 10	14	5	9	
Preoperative BMI (kg/m ²)				
< 25	24	8	16	0.95
\geq 25	52	17	35	
Preoperative albumin (g/dL)				
Mean (\pm SD)	40.1 (\pm 4.5)	40.4 (\pm 4.2)	39.9 (\pm 4.6)	0.67
pT*				
Tis /T1	24	11	13	0.35
T2	15	4	11	
T3	26	6	20	
T4	11	4	7	
pN*				
N0	42	12	30	0.54
N1	16	7	9	
N2/N3	18	6	12	
pTNM*				
0 / I	31	12	19	0.44
II	29	7	22	
III	16	6	10	
Type of operation				
Subtotal gastrectomy	26	14	12	0.005
Total gastrectomy	50	11	39	
Neoadjuvant chemotherapy				
Yes	10	2	8	0.35
No	66	23	43	
Adjuvant therapy				
Yes	16	4	12	0.44
No	60	21	39	
Dindo-Clavien grade				
0 -I	36	12	24	0.93
\geq II	40	13	27	
Anastomotic leak	9	2	7	0.72
Sepsis				
Yes	15	3	12	0.23
No	61	22	39	

ASA, American Society of Anesthesiologists, BMI: Body mass index. *According to the 7th edition of the International Union Against Cancer tumor, node metastasis staging system (18). Results are expressed as number of patients unless otherwise stated.

Table 2. EORTC QLQ-C30 and QLQ-STO-22 scales/items before and 2 years after gastric cancer resection in relation to weight loss \geq or $<$ 10% at 2 years.

EORTC QLQ C-30 scales/items	Before Surgery N= 72			2 Years After Surgery N= 76		
	Weight loss < 10% N=24	Weight loss \geq 10% N=48	MSD	Weight loss < 10% N=25	Weight loss \geq 10% N=51	MSD
	Functional scales*					
Global health	74.6 (66 to 83)	65.6 (58 to 72)	-9	71.7 (64 to 80)	64.7 (60 to 71)	-7
Physical function	91.4 (86 to 96)	81 (76 to 88)	-10.4	87.2 (81 to 94)	79.9 (76 to 87)	-7.3
Role function	93.7 (88 to 99)	77.4 (69 to 89)	- 16.3	90 (84 to 96)	82 (78 to 90)	-8
Emotional function	76 (67 to 84)	68.9 (64 to 77)	-7.1	76.7 (66 to 87)	74.4 (70 to 83)	-2.3
Cognitive function	84 (77 to 91)	85.4 (80 to 92)	1.4	83.3 (75 to 91)	78.1 (74 to 87)	-5.2
Social function	90.3 (84 to 97)	86.4 (80 to 93)	-3.9	91.3 (83 to 99)	85.3 (80 to 93)	-6
Symptom scales/items**						
Fatigue	16.7 (8 to 25)	36.9 (26 to 43)	20	21.8 (12 to 31)	31.1 (24 to 35)	9.3
Nausea and vomiting	4.2 (0 to 8)	7.9 (2 to 10)	3.7	8 (2 to 14)	16.3 (6 to 20)	8.3
Pain	9.7 (3 to 16)	26 (16 to 31)	16.3	6 (1 to 11)	23.2 (14 to 29)	17.2
Dyspnoea	0	7.6 (0 to 14)	7.6	5.3 (0 to 10)	6.5 (2 to 12)	1.2
Insomnia	22.2 (9 to 36)	29.9 (19 to 39)	7.7	26.7 (12 to 41)	24.2 (14 to 31)	-2.5
Appetite loss	20.8 (8 to 33)	26.4 (14 to 34)	5.6	20 (7 to 32)	20 (10 to 24)	-
Constipation	22.2 (9 to 35)	33.3 (23 to 42)	11.1	14.7 (4 to 25)	8.8 (2 to 15)	-5.9
Diarrhoea	6.9 (-1 to 15)	7.6 (1 to 13)	0.7	10.6 (4 to 17)	20.6 (11 to 27)	10
Financial difficulties	5.5 (0 to 11)	12.3 (4 to 20)	6.8	6.7 (0 to 13)	18.7 (8 to 26)	12
EORTC QLQ-STO-22 scales/items**						
Dysphagia	5.5 (0 to 12)	9.9 (4 to 12)	4.4	6.9 (-2 to 16)	14.2 (9 to 18)	7.2
Pain	12.8 (4 to 23)	20.4 (12 to 26)	7.6	8.7 (1 to 16)	23.1 (15 to 31)	14.4
Reflux symptoms	11.8 (2 to 24)	9 (6 to 13)	2.8	11.3 (4 to 19)	14.4 (8 to 18)	3.1
Eating restrictions	8.7 (2 to 16)	16.3 (9 to 22)	7.6	14.4 (8 to 25)	26.1 (18 to 34)	11.7
Anxiety	44.4 (32 to 52)	45.2 (37 to 51)	0.8	25 (12 to 31)	33.8 (24 to 40)	8.8
Having dry mouth	25 (11 to 42)	34.7 (23 to 43)	9.7	27.1 (13 to 47)	34 (21 to 41)	6.9
Taste	6.9 (-2 to 18)	11.8 (3 to 18)	4.9	10.7 (-2 to 18)	18.9 (12 to 34)	8.2
Body image	13.8 (3 to 30)	15.3 (4 to 21)	1.5	17.3 (5 to 31)	23.5 (4 to 21)	6.2
Hair loss	6 (-1 to 15)	12.7 (0 to 14)	6.7	13.9 (0 to 23)	6.8 (0 to 14)	-7.1

Results are expressed as mean (95% CI). Abbreviation: EORTC QLQ, European Organization for Research and treatment of cancer Quality of Life Questionnaire –C30 and STO22; *Higher score represent better function; ** Higher score represent more symptoms. MSD: Mean score difference.

Table 3. Percentage of patients reporting “quite a bit” or “very much” with regard to symptoms before and 2 years after gastric cancer resection in relation to weight loss \geq or $<$ 10% at 2 years

	Before Surgery N= 72				2 Years After Surgery N=76			
	Weight loss < 10% N= 24		Weight loss \geq 10% N= 48		Weight loss < 10% N=25		Weight loss \geq 10% N= 51	
QLQ-C30								
Fatigue	12.5	(4 to 31)	36.9	(23 to 49)	20	(9 to 39)	20.4	(11 to 32)
Nausea and vomiting	-		10.4	(1 to 22)	-		13.7	(7 to 26)
Pain	4.1	(1 to 20)	20.8	(12 to 34)	-		21.6	(12 to 35)
Dyspnoea	-		6.2	(2 to 17)	-		2	(1 to 10)
Insomnia	16.7	(7 to 36)	25	(15 to 39)	24	(11 to 43)	19.6	(11 to 32)
Appetite loss	16.7	(7 to 36)	22.9	(13 to 36)	20	(9 to 39)	14	(7 to 26)
Constipation	12.5	(4 to 31)	31.2	(20 to 45)	8	(2 to 25)	6.1	(2 to 16)
Diarrhoea	8.3	(2 to 26)	6.2	(2 to 17)	-		13.7	(7 to 26)
Financial difficulty	-		10.9	(4 to 22)	4	(1 to 19)	16	(8 to 28)
QLQ-STO22								
Dysphagia	25	(12 to 45)	8.5	(3 to 19)	8	(2 to 25)	11.8	(5 to 23)
Pain	17.4	(7 to 36)	18.7	(10 to 32)	4	(1 to 19)	18	(10 to 30)
Reflux symptoms	21.7	(9 to 40)	6.2	(2 to 17)	12	(4 to 30)	12	(5 to 23)
Eating restrictions	29.1	(15 to 49)	12.5	(6 to 25)	24	(11 to 43)	29.4	(19 to 43)
Anxiety	70.8	(51 to 85)	54.2	(40 to 67)	32	(17 to 52)	33	(22 to 47)
Having dry mouth	37.5	(21 to 57)	25	(15 to 39)	24	(11 to 43)	25.5	(15 to 39)
Taste	20.8	(9 to 40)	4.2	(1 to 14)	12	(4 to 30)	11.8	(5 to 23)
Body image	20.8	(9 to 40)	10.4	(4 to 22)	8	(2 to 25)	23.6	(23 to 36)
Hair loss	13.6	(4 to 31)	19.1	(10 to 32)	17	(6 to 34)	10	(4 to 20)

Results are expressed as percentages (95% CIs). Abbreviation: EORTC QLQ, European Organization for Research and treatment of cancer Quality of Life Questionnaire –C30 and STO22; CI confidence interval. * Higher scores represent greater proportion of individuals reporting (3) “quite a bit” or (4) “very much” with regard to symptoms (severe symptoms).